A new study from the University of Edinburgh sheds light on why some tumors may respond better than others to a cutting-edge class of cancer drugs called PROTACs (Proteolysis Targeting Chimeras). Unlike traditional drugs that merely block harmful proteins, PROTACs are designed to eliminate them entirely by hijacking the cell's own waste-disposal system — a potentially more powerful approach for cancers driven by protein overload.

The key finding? Why a protein accumulates matters just as much as how much of it is present. Using β-catenin — a protein implicated in many cancers — researchers showed that PROTACs were highly effective when the protein built up due to faulty breakdown, reducing levels to a consistent minimum regardless of the starting amount. But when cancer cells were simply producing more protein, treatment left elevated levels behind because new protein kept being made.

Key Takeaways:

• PROTACs are more effective against proteins that accumulate due to impaired degradation vs. overproduction
• Tumor genetics — not just protein quantity — may predict PROTAC treatment response
• Findings support a more personalized approach to matching patients with targeted protein-degradation therapies

Why it matters: As PROTACs move closer to clinical use, understanding the biological "why" behind protein accumulation could help oncologists identify which patients are most likely to benefit — making treatment smarter, not just stronger.